Lin Ying-Li, Wang Yan-Ling, Fu Xing-Li, Li Wen-Ping, Wang Yu-Hao, Ma Jian-Guo
Department of Urology, Xuzhou Cancer Hospital, Affiliated Xuzhou Hospital of Jiangsu University, Xuzhou, 221000, Jiangsu, China.
Department of Anesthesiology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, Guangdong, China.
Oncotarget. 2016 May 10;7(19):28384-92. doi: 10.18632/oncotarget.8635.
Bladder cancer is a heterogeneous disease with outcome difficult to predict, and novel predictive biomarkers are needed. PCDH7, a member of protocadherins family, functions as tumor suppressor in several human cancers. The human PCDH7 gene is localized in chromosome 4p15, which is often inactivated in human cancers, including bladder cancer. The aim of this study was to investigate the clinical significance of PCDH7 expression in non-muscle invasive bladder cancer (NMIBC). PCDH7 expression was examined using immunohistochemical staining in 199 primary NMIBC tissues and 25 normal bladder epithelial tissues. Then the relationship between PCDH7 expression and clinicopathologic features was evaluated. Kaplan-Meier survival analysis and Cox analysis was used to evaluate the correlation between PCDH7 expression and prognosis. PCDH7 expression in NMIBC tissues was significantly lower than that in normal bladder epithelial tissues (P < 0.001). Low PCDH7 expression correlated with advanced grade (P = 0.021) and larger tumor size (P = 0.044). Moreover, patients with low PCDH7 expression have shorter recurrence-free survival (P < 0.001), progression-free survival (P = 0.007) and overall survival (P = 0.011) than patients with high PCDH7 expression. Low PCDH7 expression is an independent predictor of recurrence-free survival (multivariate Cox analysis: P = 0.007), progression-free survival (multivariate Cox analysis: P = 0.014) and overall survival (multivariate Cox analysis: P = 0.004). The findings indicate that low PCDH7 expression is a potential prognostic biomarker for primary NMIBC.
膀胱癌是一种异质性疾病，其预后难以预测，因此需要新的预测性生物标志物。原钙黏蛋白7（PCDH7）是原钙黏蛋白家族的成员之一，在多种人类癌症中发挥肿瘤抑制作用。人类PCDH7基因定位于4号染色体p15区域，该区域在包括膀胱癌在内的人类癌症中常发生失活。本研究旨在探讨PCDH7表达在非肌层浸润性膀胱癌（NMIBC）中的临床意义。采用免疫组织化学染色法检测了199例原发性NMIBC组织和25例正常膀胱上皮组织中PCDH7的表达情况。然后评估了PCDH7表达与临床病理特征之间的关系。采用Kaplan-Meier生存分析和Cox分析评估PCDH7表达与预后的相关性。NMIBC组织中PCDH7的表达明显低于正常膀胱上皮组织（P<0.001）。PCDH7低表达与高级别（P=0.021）和更大的肿瘤大小（P=0.044）相关。此外，与PCDH7高表达的患者相比，PCDH7低表达的患者无复发生存期（P<0.001）、无进展生存期（P=0.007）和总生存期（P=0.011）更短。PCDH7低表达是无复发生存期（多因素Cox分析：P=0.007）、无进展生存期（多因素Cox分析：P=0.014）和总生存期（多因素Cox分析：P=0.004）的独立预测因素。这些发现表明，PCDH7低表达是原发性NMIBC潜在的预后生物标志物。
